JAK2 and essential thrombocythemia: These mutations are also found in rare cases of myeloproliferative disorders like ET and primary myelofibrosis and can result in a loss of function of the ubiquitin E3 ligase activity, thereby disrupting the ubiquitin/proteasome‐mediated degradation of MPL/JAK2.18